The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.
 
Ferdinandos Skoulidis
No Relationships to Disclose
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Genentech/Roche
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Pfizer
 
Hira Rizvi
No Relationships to Disclose
 
Brett W. Carter
No Relationships to Disclose
 
Warren Denning
No Relationships to Disclose
 
Yasir Elamin
No Relationships to Disclose
 
Jianjun Zhang
No Relationships to Disclose
 
Giulia Costanza Leonardi
No Relationships to Disclose
 
Darragh Halpenny
No Relationships to Disclose
 
Andrew Plodkowski
No Relationships to Disclose
 
Niamh Long
No Relationships to Disclose
 
Jeremy J. Erasmus
No Relationships to Disclose
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Kwok-Kin Wong
No Relationships to Disclose
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - Ariad; AstraZeneca; Asuragen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; GE Healthcare; Genecentric; Genentech/Roche; GlaxoSmithKline; HTG Molecular Diagnostics; Lilly; Lilly; Pfizer; Synta
Speakers' Bureau - Boehringer Ingelheim; Medscape; Pfizer
Research Funding - Bayer; Genentech; HTG Molecular Diagnostics; Jounce Therapeutics; Merck; Myriad Genetics; OncoPlex Diagnostics
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Merrimack; Pfizer; Roche
Research Funding - Astellas Pharma; AstraZeneca
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Genentech; Medivation; Novartis; Oncomed; Synta
Research Funding - AstraZeneca (Inst)